Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the National Cancer Data Base

BACKGROUNDPrevious studies have suggested that esophagectomy is severely underused for patients with resectable esophageal cancer. The recent expansion of endoscopic local therapies, advances in surgical techniques, and improved postoperative outcomes have changed the therapeutic landscape. The impact of these developments and evolving treatment guidelines on national practice patterns is unknown. METHODSPatients diagnosed with clinical stage 0 to III esophageal cancer were identified from the National Cancer Database (2004-2013). The receipt of potentially curative surgical treatment over time was analyzed, and multivariate logistic regression was used to identify factors associated with surgical treatment. RESULTSThe analysis included 52,122 patients. From 2004 to 2013, the overall rate of potentially curative surgical treatment increased from 36.4% to 47.4% (P<.001). For stage 0 disease, the receipt of esophagectomy decreased from 23.8% to 17.9% (P<.001), whereas the use of local therapies increased from 34.3% to 58.8% (P<.001). The use of surgical treatment increased from 43.4% to 61.8% (P<.001), from 36.1% to 45.0% (P<.001), and from 30.8% to 38.6% (P<.001) for patients with stage I, II, and III disease, respectively. In the multivariate analysis, divergent practice patterns and adherence to national guidelines were noted between academic and community facilities. CONCLUSIONSThe use of potentially curative surgical treatment has increased for patients with stage 0 to III esophageal cancer. The expansion of local therapies has driven increased rates of surgical treatment for early-stage disease. Although the increased use of esophagectomy for more advanced disease is encouraging, significant variation persists at the patient and facility levels. Cancer 2017;123:410-419. (c) 2016 American Cancer Society. National use of potentially curative surgical treatment increased from 36.4% in 2004 to 47.4% in 2013 for patients with stage 0 to III esophageal cancer. The adoption of endoscopic local therapies has predominated for early-stage disease, whereas an encouraging increase in the use of esophagectomy for locoregional disease has been observed.